Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).
Journal article

Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).

  • Weller, Michael Laboratory of Molecular Neuro-Oncology, Department of Neurology, and Neuroscience Center Zurich, University Hospital and University of Zurich, Zurich, Switzerland;
  • Reifenberger, Guido Department of Neuropathology, Heinrich Heine University Hospital, Düsseldorf, Germany;
  • Le Rhun, Emilie Lille University Hospital, Lille, France;
  • Clarke, Jennifer Leigh University of California, San Francisco, San Francisco, CA;
  • Soffietti, Riccardo Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin, Italy;
  • Wick, Antje Neurology Clinic, University of Heidelberg, National Center for Tumor Diseases, Heidelberg, Germany;
  • Chinot, Olivier L. Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France;
  • Ducray, Francois Service de Neuro-oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Lyon, France;
  • Hau, Peter University of Regensburg, Regensburg, Germany;
  • McDonald, Kerrie Leanne University of NSW, Kensington, Australia;
  • Marosi, Christine University of Vienna, Wien, Austria;
  • Schnell, Oliver Department of Neurosurgery, University Hospital Munich LMU, Munich, Germany;
  • Hottinger, Andreas Felix CHUV University Hospital, Lausanne, Switzerland;
  • Reijneveld, Jaap C. Department of Neurology, VU University Medical Center, Amsterdam, Netherlands;
  • Lombardi, Giuseppe Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy;
  • Wen, Patrick Y. Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA;
  • Klein, Martin VU Amsterdam, Amsterdam, Netherlands;
  • Gorlia, Thierry EORTC Headquarters, Brussels, Belgium;
  • Felsberg, Joerg Department of Neuropathology, Heinrich Heine University Hospital, Düsseldorf, Germany;
  • Hertler, Caroline University Hospital Zurich, Department of Neurology, Zurich, Switzerland;
Show more…
Published in:
  • Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2019, vol. 37, no. 15_suppl, p. 2056-2056
English 2056 Background: Glioblastoma represents the most aggressive primary brain tumor in adults, and less than 5% of patients survive 5 years from diagnosis. Factors influencing this long-term survival are poorly understood. Methods: In cooperation with the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium, more than 20 clinical sites in the US, Europe and Australia have registered patients with centrally confirmed glioblastoma who survived ≥ 5 years, collecting clinical data including therapy and quality of life-related factors, as well as biospecimens allowing to analyse molecular and immunological parameters. Results: At the cut-off of December 31, 2018, 392 patients were registered, of which 232 had glioblastoma confirmed by central pathology review; 59 dropped out due to histology other than glioblastoma. Glioblastomas were isocitrate dehydrogenase (IDH)-wildtype in 70.7% and had a positive O6-methylguanine DNA methyltransferase (MGMT) promotor methylation status in 75.9%. Median age at diagnosis was 52 years (range: 21-77 years). There was enrichment for patients with gross total resection. Further analyses are ongoing. Conclusions: In a comprehensive effort, the consortium funded by the US Brain Tumor Funders’ Collaborative characterizes factors modulating long-term survival in glioblastoma in a unique large patient cohort. Clinical trial information: NCT 03770468.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/41662
Statistics

Document views: 22 File downloads: